[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Grunhagen DJ, de Wilt JH, Graveland WJ, Verhoef C, van Geel AN, Eggermont AM: Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer; 2006 Apr 15;106(8):1776-84
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma.
  • BACKGROUND: Extensive and mutilating surgery is often required for locally advanced soft tissue sarcoma (STS) of the limb.
  • As it has become apparent that amputation for STS does not improve survival rates, the interest in limb-preserving approaches has increased.
  • Isolated limb perfusion (ILP) with tumor necrosis factor-alpha (TNF) and melphalan is successful in providing local tumor control and enables limb-preserving surgery in a majority of cases.
  • ILPs were performed at mild hyperthermic conditions with 1-4 mg of TNF and 10-13 mg/L limb-volume melphalan (M) for leg and arm perfusions, respectively.
  • Limb salvage was achieved in 87% of the perfused limbs.
  • Median survival post-ILP was 57 months and prognostic factors for survival were Trojani grade of the tumor and ILP for single versus multiple STS.
  • The procedure could be performed safely, with a perioperative mortality of 0.5% in all patients with no age limit (median age, 54 yrs; range, 12-91).
  • CONCLUSION: TNF+M-based ILP can provide limb salvage in a significant percentage of patients with locally advanced STS and has therefore gained a permanent place in the multimodality treatment of STS.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Chemotherapy, Cancer, Regional Perfusion. Extremities. Limb Salvage. Melphalan / administration & dosage. Sarcoma / drug therapy. Tumor Necrosis Factor-alpha / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Prognosis. Recombinant Proteins / administration & dosage. Survival Rate

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 American Cancer Society
  • (PMID = 16541435.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Recombinant Proteins; 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  •  go-up   go-down


2. van Ginkel RJ, Thijssens KM, Pras E, van der Graaf WT, Suurmeijer AJ, Hoekstra HJ: Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: three time periods at risk for amputation. Ann Surg Oncol; 2007 Apr;14(4):1499-506
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: three time periods at risk for amputation.
  • BACKGROUND: The aim of this study was to investigate the long-term limb salvage rate and overall survival after isolated limb perfusion (ILP) with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma (STS).
  • Limb salvage and overall survival curves were calculated by the Kaplan-Meier method.
  • Overall 1, 5, and 10 years' limb salvage was 80.1% +/- 4.8%, 68.2% +/- 6.5%, and 60.6% +/- 9.2%, respectively.
  • We found that the risk of amputation was linked to three time periods.
  • The first was within a year after perfusion, mainly as a result of massive necrosis of the tumor and overlying skin, resulting in soft tissue deficit or recurrent disease (n = 17).
  • The third occurred 10 years after perfusion, with two amputations performed for critical leg ischemia.
  • Another two patients developed a pathological fracture of the femur due to radiation osteonecrosis.
  • CONCLUSIONS: ILP treatment with tumor necrosis factor alpha and melphalan followed by delayed surgical resection and adjuvant radiation treatment is an effective limb salvage treatment regimen for locally advanced STS.
  • However, we observed late morbidity, with two amputations performed for critical leg ischemia and two pathological fractures of the femur in patients receiving adjuvant radiotherapy.
  • [MeSH-major] Amputation. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Melphalan / administration & dosage. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant. Risk Factors. Survival Rate. Tumor Necrosis Factor-alpha / administration & dosage

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):745-50 [11020571.001]
  • [Cites] Cancer. 1989 Aug 1;64(3):616-21 [2743257.001]
  • [Cites] Eur J Surg Oncol. 2000 Dec;26(8):792-7 [11087648.001]
  • [Cites] Ann Surg Oncol. 2002 May;9(4):355-63 [11986187.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2235-41 [12103287.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1117-27 [12829150.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1483-90 [14508836.001]
  • [Cites] Radiology. 1971 Nov;101(2):429-33 [5114783.001]
  • [Cites] Br J Radiol. 1974 Feb;47(554):157-8 [4817460.001]
  • [Cites] Radiat Res. 1975 Jul;63(1):157-64 [1144676.001]
  • [Cites] Ann Surg. 1977 May;185(5):555-64 [266397.001]
  • [Cites] Ann Surg. 1980;192(4):431-8 [6932827.001]
  • [Cites] Cancer. 1981 May 1;47(9):2269-74 [7226121.001]
  • [Cites] Ann Surg. 1982 Sep;196(3):305-15 [7114936.001]
  • [Cites] Cancer. 1984 Jun 15;53(12):2579-84 [6372980.001]
  • [Cites] Cancer. 1986 Jul 15;58(2):306-9 [3719523.001]
  • [Cites] Am J Surg. 1988 May;155(5):667-71 [3369621.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Nov;21(6):1485-92 [1938557.001]
  • [Cites] J Clin Oncol. 1992 Jan;10(1):52-60 [1727926.001]
  • [Cites] Cancer. 1994 Apr 15;73(8):2140-6 [8156518.001]
  • [Cites] Arch Surg. 1995 Jan;130(1):43-7 [7802575.001]
  • [Cites] Ann Surg Oncol. 1994 Sep;1(5):382-8 [7850539.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 30;32(5):1289-300 [7635768.001]
  • [Cites] Arch Surg. 1996 Jun;131(6):672-4 [8645079.001]
  • [Cites] Crit Care Med. 1996 May;24(5):765-70 [8706451.001]
  • [Cites] Eur J Surg Oncol. 1996 Oct;22(5):528-31 [8903498.001]
  • [Cites] Ann Surg. 1996 Dec;224(6):756-64; discussion 764-5 [8968230.001]
  • [Cites] Cancer. 1997 Mar 15;79(6):1129-37 [9070490.001]
  • [Cites] Lancet. 1997 Dec 6;350(9092):1647-54 [9400508.001]
  • [Cites] Clin Orthop Relat Res. 1998 Jul;(352):168-78 [9678045.001]
  • [Cites] Cancer Treat Rev. 1998 Dec;24(6):373-91 [10189405.001]
  • [Cites] Ann Surg. 1958 Oct;148(4):616-32 [13583933.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):619-25 [16446334.001]
  • [Cites] Eur J Surg Oncol. 2000 Nov;26(7):669-78 [11078614.001]
  • (PMID = 17253101.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  • [Other-IDs] NLM/ PMC1914273
  •  go-up   go-down


3. Thanni LO: Extremity haemangiopericytoma, a case report from Nigeria. Afr Health Sci; 2005 Sep;5(3):261-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Haemangiopericytoma is an uncommon soft tissue sarcoma of vascular origin.
  • It occurs more frequently in the extremities than elsewhere in the body although it can arise in any organ.
  • Wide surgical excision is the mainstay of treatment.
  • However, adjuvant radiotherapy and chemotherapy are desirable because the malignant nature of this tumour is frequently unpredictable.
  • Adjuvant therapy is recommended for metastases, recurrence and incomplete resection.
  • Long term follow up is essential in all cases as recurrence can occur several years after treatment.
  • Where little or no experience with managing this tumor exists, it is important to be aware of its clinical behaviour and the treatment options, hence this case reports.
  • [MeSH-major] Hemangiopericytoma / diagnosis. Leg / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Formos Med Assoc. 2000 May;99(5):428-30 [10870335.001]
  • [Cites] Radiology. 1960 May;74:721-30 [13825130.001]
  • [Cites] Head Neck. 2004 Jun;26(6):544-9 [15162357.001]
  • [Cites] J Foot Ankle Surg. 2004 May-Jun;43(3):191-4 [15181437.001]
  • [Cites] J Reprod Med. 2004 May;49(5):404-7 [15214720.001]
  • [Cites] Tumori. 2004 Mar-Apr;90(2):265-8 [15237597.001]
  • [Cites] Ann Surg. 1974 Feb;179(2):128-32 [4359454.001]
  • [Cites] Hum Pathol. 1976 Jan;7(1):61-82 [1244311.001]
  • [Cites] Am J Surg. 1979 Mar;137(3):413-6 [434338.001]
  • [Cites] Am J Surg. 1984 Sep;148(3):372-4 [6476228.001]
  • [Cites] Z Orthop Ihre Grenzgeb. 1989 Sep-Oct;127(5):611-5 [2596154.001]
  • [Cites] Jpn J Thorac Cardiovasc Surg. 1998 Jun;46(6):523-5 [9720371.001]
  • [Cites] Int Orthop. 1999;23(3):184-6 [10486035.001]
  • [Cites] Virchows Arch. 2004 Sep;445(3):315-9 [15243738.001]
  • [Cites] Clin Neurol Neurosurg. 2003 Jul;105(3):159-66 [12860507.001]
  • (PMID = 16245998.001).
  • [ISSN] 1729-0503
  • [Journal-full-title] African health sciences
  • [ISO-abbreviation] Afr Health Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Uganda
  • [Other-IDs] NLM/ PMC1831924
  •  go-up   go-down


Advertisement
4. Grunhagen DJ, de Wilt JH, Graveland WJ, van Geel AN, Eggermont AM: The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma. Cancer; 2006 Jan 1;106(1):156-62
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma.
  • BACKGROUND: Both patients with soft tissue sarcoma (STS) and patients with melanoma have limited treatment possibilities once the tumor has metastasized systemically.
  • In patients with extremity STS or bulky melanoma in-transit metastases, the local tumor burden may be so problematic that, even in patients with systemically metastasized disease, an amputation may be inevitable.
  • Isolated limb perfusion (ILP) has proven to be an excellent, local, limb-saving treatment option in patients with locally advanced extremity tumors.
  • In this study, the authors investigated the palliative value of the ILP procedure to avoid amputation in patients who had Stage IV STS and melanoma.
  • METHODS: From 1991 to 2003, of 339 tumor necrosis factor alpha (TNF)-based ILPs, 51 procedures were performed for either Stage IV STS (n = 37 patients) or Stage IV melanoma (n = 14 patients).
  • All patients underwent an ILP with TNF and melphalan of the upper limb (n = 4 patients) or the lower limb (n = 47 patients) with 26-140 mg melphalan and 2-4 mg TNF.
  • Limb salvage was achieved in 36 of 37 patients, with 1 patient undergoing amputation due to treatment toxicity.
  • All patients with melanoma preserved their limb during a median survival of 7 months.
  • CONCLUSIONS: TNF-based ILP is an excellent procedure that provided tumor control and limb salvage for the short survival of patients with metastasized, very bulky, limb-threatening tumors of the extremity.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Melanoma / drug therapy. Melphalan / therapeutic use. Palliative Care. Sarcoma / drug therapy. Tumor Necrosis Factor-alpha / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Amputation. Arm. Female. Humans. Leg. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Recombinant Proteins / administration & dosage. Recombinant Proteins / adverse effects. Recombinant Proteins / therapeutic use

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 16323177.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Recombinant Proteins; 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  •  go-up   go-down


5. Lee JR, Georgi DE, Wang BY: Malignant myoepithelial tumor of soft tissue: a report of two cases of the lower extremity and a review of the literature. Ann Diagn Pathol; 2007 Jun;11(3):190-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant myoepithelial tumor of soft tissue: a report of two cases of the lower extremity and a review of the literature.
  • Myoepithelial tumors of the soft tissues have only recently been described.
  • Two cases of lower extremity malignant myoepithelial tumors are reported.
  • One case of malignant mixed tumor overlying the gastrocnemius muscle was treated with wide local excision, but metastasized to regional lymph nodes 14 months after surgical excision.
  • One patient with malignant myoepithelioma of the right lower leg was treated with limb amputation and is alive without disease at 46 months.
  • A review of the literature discloses 120 additional cases of soft tissue myoepithelial tumors, 102 of which are myoepitheliomas and 18 are mixed tumors.
  • Of these, 30% had locally recurrent disease and 32% developed metastatic disease.
  • Treatment benefit from chemotherapy and radiation therapy is unclear.
  • [MeSH-major] Myoepithelioma / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Calcium-Binding Proteins / metabolism. Cell Proliferation. Glial Fibrillary Acidic Protein / metabolism. Humans. Leg / pathology. Male. Microfilament Proteins / metabolism. Middle Aged. Mixed Tumor, Malignant / diagnosis. Mixed Tumor, Malignant / pathology. Necrosis / pathology. Phosphopyruvate Hydratase / metabolism. Vimentin / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17498593.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / Glial Fibrillary Acidic Protein; 0 / Microfilament Proteins; 0 / Vimentin; 0 / calponin; EC 4.2.1.11 / Phosphopyruvate Hydratase
  • [Number-of-references] 35
  •  go-up   go-down


6. Russell H, Hicks MJ, Bertuch AA, Chintagumpala M: Infantile fibrosarcoma: clinical and histologic responses to cytotoxic chemotherapy. Pediatr Blood Cancer; 2009 Jul;53(1):23-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infantile fibrosarcoma: clinical and histologic responses to cytotoxic chemotherapy.
  • BACKGROUND: Infantile fibrosarcoma (IF) is a rare soft tissue sarcoma that presents either at birth or in the first year of life.
  • Complete surgical resection is usually curative but chemotherapy may shrink the tumor to facilitate complete resection.
  • This report describes the histologic changes and outcomes in four patients with IF treated with chemotherapy and surgical resection.
  • PROCEDURE: A retrospective review was performed of patients treated between 2000 and 2007.
  • The patients were diagnosed from birth up to 7 months of age; three had lower extremity tumors and one had a neck tumor.
  • All patients received vincristine, cyclophosphamide, and actinomycin; one patient also received ifosfamide and etoposide after tumor progression.
  • One tumor, arising from the neck, had rapid shrinkage.
  • Two lower extremity tumors had only modest changes in dimensions but upon resection, the tumor bed contained fibrous tissue with exaggerated small caliber vessels.
  • The fourth infant developed metastatic lesions in the central nervous system, orbits, lungs, and kidney after complete removal of the primary tumor.
  • The metastatic lesions responded to chemotherapy and have remained stable for over 3 years.
  • CONCLUSIONS: IF is a chemosensitive tumor.
  • In patients where a clinical response is not apparent, cytoreduction of the tumor and replacement with fibrotic and fibrovascular tissue may facilitate gross-total resection.
  • The chemotherapy-responsiveness of this tumor may abrogate unfavorable features such as metastatic or residual tumor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fibrosarcoma / drug therapy. Fibrosarcoma / pathology
  • [MeSH-minor] Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Female. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / surgery. Humans. Infant. Infant, Newborn. Leg. Lymphatic Metastasis. Male. Retrospective Studies. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Wiley-Liss, Inc.
  • (PMID = 19340853.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


7. Wessalowski R, Schneider DT, Mils O, Hannen M, Calaminus G, Engelbrecht V, Pape H, Willers R, Engert J, Harms D, Göbel U: An approach for cure: PEI-chemotherapy and regional deep hyperthermia in children and adolescents with unresectable malignant tumors. Klin Padiatr; 2003 Nov-Dec;215(6):303-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An approach for cure: PEI-chemotherapy and regional deep hyperthermia in children and adolescents with unresectable malignant tumors.
  • BACKGROUND: Elevated temperatures of 40 - 44 degrees C increase the actions of various anticancer drugs including N-lost derivatives, cytotoxic antibiotics and platinum analoga.
  • In clinical usage thermochemotherapy (TCH) should facilitate surgical resection and ameliorate local tumor control.
  • Among these, 24 patients had extracranial non-testicular germ cell tumors and 15 patients soft tissue or chondrosarcomas.
  • INDICATION: locoregional relapse (n = 29) or unresectable tumor after neoadjuvant chemotherapy (n = 10).
  • Among these two groups, there were ten patients with poor response or progressive disease under primary or relapse chemotherapy.
  • Tumor site: pelvis (30), abdomen (4), head and neck (2), proximal leg (2) and lumbar spine (1).
  • TCH was followed by surgical tumor resection in 28/39 patients and/or radiotherapy in 13/39 patients.
  • CONCLUSION: TCH shows substantial therapeutic efficacy and facilitates complete tumor resection in 14 out of 28 operated patients.
  • Multimodal treatment including TCH, surgical resection and/or radiotherapy leads to sustained remission in the majority of patients with locoregional tumor recurrence.
  • The therapeutic effect is most pronounced, if TCH is administered at first relapse.
  • Therefore, a more valid assessment of treatment efficacy can only be made by a matched-pair comparison in cooperation with the clinical registers.
  • [MeSH-major] Abdominal Neoplasms / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / therapy. Chondrosarcoma / therapy. Cisplatin / therapeutic use. Etoposide / therapeutic use. Germinoma / therapy. Head and Neck Neoplasms / therapy. Hyperthermia, Induced. Ifosfamide / therapeutic use. Lumbar Vertebrae. Pelvic Neoplasms / therapy. Sarcoma / therapy. Soft Tissue Neoplasms / therapy. Spinal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Chi-Square Distribution. Child. Child, Preschool. Combined Modality Therapy. Data Interpretation, Statistical. Female. Follow-Up Studies. Humans. Infant. Karnofsky Performance Status. Male. Neoadjuvant Therapy. Neoplasm Recurrence, Local. Time Factors. Treatment Outcome


8. Mula V, Mandal A, Britton E, Shanker VS: Direct bony invasion of malignant melanoma. Indian J Orthop; 2009 Oct;43(4):420-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 75-year-old Caucasian lady presented with a small papillary lesion in the region of a recurrent chronic cellulitis on the lower third of the lateral aspect of the right leg.
  • Radiological investigations by X-ray and magnetic resonance imaging revealed malignant infiltration of the tibia in its mid and lower third with two soft tissue metastatic masses adjacent.
  • She underwent a further above-knee amputation followed by chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Orthopedics. 2001 Mar;24(3):225, 307-8 [11300284.001]
  • [Cites] J Bone Joint Surg Am. 2001 Nov;83-A(11):1713-7 [11701796.001]
  • [Cites] Arch Pathol Lab Med. 2000 Dec;124(12):1780-4 [11100057.001]
  • [Cites] J Laryngol Otol. 2000 May;114(5):378-80 [10912271.001]
  • [Cites] Can J Surg. 2000 Apr;43(2):137-9 [10812349.001]
  • [Cites] J Hand Surg Am. 2000 Mar;25(2):365-9 [10722831.001]
  • [Cites] Int J Clin Oncol. 2007 Aug;12(4):305-8 [17701013.001]
  • [Cites] Ear Nose Throat J. 2007 Jul;86(7):388-90 [17702316.001]
  • [Cites] J Cutan Med Surg. 2006 Jan-Feb;10(1):36-40 [17241571.001]
  • [Cites] Europace. 2006 Jul;8(7):545-8 [16798769.001]
  • [Cites] Am Surg. 2006 Jan;72(1):98-100 [16494196.001]
  • [Cites] J Hand Surg Am. 2005 May;30(3):615-9 [15925176.001]
  • [Cites] Ann Surg Oncol. 1999 Jun;6(4):336-44 [10379853.001]
  • [Cites] Arch Pathol Lab Med. 1999 Feb;123(2):163-6 [10050793.001]
  • [Cites] J Laryngol Otol. 2004 May;118(5):382-4 [15165318.001]
  • [Cites] J Hand Surg Am. 2004 Mar;29(2):194-200 [15043888.001]
  • [Cites] Clin Nucl Med. 2003 Dec;28(12):961-5 [14663316.001]
  • [Cites] Mol Imaging Biol. 2002 Oct;4(5):359-62 [14537111.001]
  • [Cites] Rom J Gastroenterol. 2002 Mar;11(1):53-6 [12096315.001]
  • [Cites] J Hand Surg Am. 2000 Nov;25(6):1169-72 [11119681.001]
  • (PMID = 19838397.001).
  • [ISSN] 1998-3727
  • [Journal-full-title] Indian journal of orthopaedics
  • [ISO-abbreviation] Indian J Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2762569
  • [Keywords] NOTNLM ; Bone tumor / direct invasion / malignant melanoma / metastatic melanoma
  •  go-up   go-down


9. Lejeune FJ, Pujol N, Liénard D, Mosimann F, Raffoul W, Genton A, Guillou L, Landry M, Chassot PG, Chiolero R, Bischof-Delaloye A, Leyvraz S, Mirimanoff RO, Bejkos D, Leyvraz PF: Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. Eur J Surg Oncol; 2000 Nov;26(7):669-78
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities.
  • AIMS: Patients with non-resectable soft tissue sarcomas of the extremities do not live longer if they are treated by amputation or disarticulation.
  • In order to avoid major amputations, we tested isolated limb perfusion (ILP) with tumour necrosis factor alpha (TNF)+melphalan+/-interferon-gamma (IFN) as a pre-operative, neoadjuvant limb salvage treatment.
  • METHODS: Twenty-two patients were included (six men and 16 women; three upper limb and 19 lower limb tumours).
  • Thirteen cases were recurrent or progressive after previous therapy; five tumours had a diameter >/=20 cm, and four were multiple or regionally metastatic.
  • Three patients had a minimal or no response and the tumour progressed in one case.
  • All patients had fever for 24 hours but only one developed a reversible grade 3 distributive shock syndrome with no sequelae.
  • Seventeen patients (77%) underwent limb-sparing resection of the tumour remnants after a median time of 3.4 months: 10 resections were intracompartmental and seven extracompartmental.
  • Adjuvant chemotherapy was given to eight patients and radiotherapy to six.
  • Secondary amputations were performed for recurrence in two patients, resulting in an overall limb salvage rate of 19/22 (86%).
  • The median disease free and overall survival times have been >12.5 and 18.7 months respectively: this is similar to the outcome after primary amputations for similar cases.
  • CONCLUSION: ILP with TNF and chemotherapy is an efficient limb sparing neoadjuvant therapy for a priori non-resectable limb soft tissue sarcomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leg / surgery. Sarcoma / drug therapy. Sarcoma / surgery. Soft Tissue Neoplasms / drug therapy. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Chemotherapy, Cancer, Regional Perfusion. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Interferon-gamma / administration & dosage. Interferon-gamma / adverse effects. Male. Melphalan / administration & dosage. Melphalan / adverse effects. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local / surgery. Radiotherapy, Adjuvant. Salvage Therapy. Survival Analysis. Tumor Necrosis Factor-alpha / administration & dosage. Tumor Necrosis Factor-alpha / adverse effects

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Harcourt Publishers Ltd.
  • (PMID = 11078614.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; 80168379AG / Doxorubicin; 82115-62-6 / Interferon-gamma; Q41OR9510P / Melphalan; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


10. Dodd LG, Major N, Brigman B: Malignant giant cell tumor of soft parts. Skeletal Radiol; 2004 May;33(5):295-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant giant cell tumor of soft parts.
  • Giant cell tumor of soft parts (GCTSP) is an extremely rare lesion with an unpredictable behavior.
  • The patient presented with a fungating skin and soft tissue mass and concurrent pulmonary nodules.
  • [MeSH-major] Giant Cell Tumors / pathology. Leg / pathology. Lung Neoplasms / diagnosis. Osteosarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Biopsy / methods. Diagnosis, Differential. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Neoplasm Recurrence, Local. Rare Diseases / drug therapy. Rare Diseases / pathology. Rare Diseases / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):248-56 [10680893.001]
  • [Cites] J Pathol. 1972 May;107(1):27-39 [4262633.001]
  • [Cites] Cancer. 1981 Feb 15;47(4):736-47 [7226022.001]
  • [Cites] Cancer. 1972 Jun;29(6):1518-29 [5031245.001]
  • [Cites] Am J Dermatopathol. 1989 Jun;11(3):197-201 [2658646.001]
  • [Cites] Mod Pathol. 1999 Sep;12 (9):894-902 [10496598.001]
  • [Cites] Am J Surg. 1978 Jul;136(1):102-6 [277073.001]
  • [Cites] Cancer. 1977 Jul;40(1):244-53 [195704.001]
  • (PMID = 14997349.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


11. Grünhagen DJ, Brunstein F, Graveland WJ, van Geel AN, de Wilt JH, Eggermont AM: Isolated limb perfusion with tumor necrosis factor and melphalan prevents amputation in patients with multiple sarcomas in arm or leg. Ann Surg Oncol; 2005 Jun;12(6):473-9
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated limb perfusion with tumor necrosis factor and melphalan prevents amputation in patients with multiple sarcomas in arm or leg.
  • BACKGROUND: Treatment for extremity soft tissue sarcoma (STS) has shifted in recent years from amputation to local wide excision combined with irradiation.
  • For multiple sarcomas, this limb-sparing approach is often not possible.
  • To avoid amputations, isolated limb perfusion (ILP) with tumor necrosis factor and melphalan is an attractive treatment option for patients with multiple extremity sarcomas.
  • All ILPs were performed under mild hyperthermic conditions by using 1 to 4 mg of tumor necrosis factor and 10 to 13 mg/L of limb volume for leg and arm perfusions, respectively.
  • The toxicity of the procedure was mild to moderate in almost all cases; no treatment-related amputation had to be performed.
  • The time to local recurrence was 29 months and differed significantly between multiple primary and multiple recurrent STS.
  • Limb salvage was achieved in 45 (82%) of 55 treated limbs.
  • CONCLUSIONS: In a group of patients who are uniformly candidates for amputation, ILP can achieve limb salvage in approximately four out of five patients.
  • Because this treatment option provides excellent local control, it should be considered before an amputation is planned.
  • [MeSH-major] Chemotherapy, Cancer, Regional Perfusion. Limb Salvage. Neoplasms, Second Primary / drug therapy. Sarcoma / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Amputation. Arm / pathology. Disease Progression. Female. Humans. Hyperthermia, Induced. Leg / pathology. Male. Middle Aged. Neoplasm Recurrence, Local. Prospective Studies. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15864484.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Bonvalot S, Missana MC, Le Cesne A, Missenard G, Vanel D, Terrier P, Le Péchoux C: [Function preserving surgery of limb sarcomas: history and improvements]. Cancer Radiother; 2006 Nov;10(6-7):416-24
MedlinePlus Health Information. consumer health - Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Function preserving surgery of limb sarcomas: history and improvements].
  • [Transliterated title] Chirurgie des sarcomes des tissus mous des membres chez l'adulte : historique et avancées thérapeutiques.
  • In the seventies, limb-sparing surgery and radiation therapy appeared capable of successfully treating the great majority of adult patients with soft tissue sarcomas of the extremities.
  • Microscopically positive surgical margins are related to a greater risk of local recurrence, whereas overall survival is compromised by high grade and large tumor size.
  • Reoperation should be a planned part of definitive management whenever the initial surgical procedure was done without a histologic diagnosis or was not planned to be a wide excision.
  • Soft tissue flap reconstruction facilitates therapy for patients with locally advanced tumors so that patients with larger tumors can undergo resection, limiting complications and limb sacrifice.
  • Isolated limb perfusion (ILP) with TNF and chemotherapy is an efficient limb-sparing neoadjuvant therapy for locally advanced limb soft tissue sarcomas.
  • [MeSH-major] Arm. Leg. Limb Salvage / methods. Sarcoma / surgery. Surgical Procedures, Operative / methods
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16890005.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 54
  •  go-up   go-down


13. Lans TE, Grünhagen DJ, de Wilt JH, van Geel AN, Eggermont AM: Isolated limb perfusions with tumor necrosis factor and melphalan for locally recurrent soft tissue sarcoma in previously irradiated limbs. Ann Surg Oncol; 2005 May;12(5):406-11
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated limb perfusions with tumor necrosis factor and melphalan for locally recurrent soft tissue sarcoma in previously irradiated limbs.
  • BACKGROUND: Recurrent extremity soft tissue sarcoma (STS) in a previously operated and irradiated area can usually be managed only by amputation.
  • Tumor necrosis factor (TNF)-alpha-based isolated limb perfusion (ILP) is an established alternative to achieve limb salvage but is assumed to require sufficient vasculature.
  • Because radiotherapy is known to destroy vasculature, we wanted to evaluate retrospectively whether the outcome of ILP in patients with radiotherapy for their primary tumor nonetheless showed a benefit from TNF treatment.
  • Limb salvage was achieved in 17 patients (65%).
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Chemotherapy, Cancer, Regional Perfusion. Limb Salvage / methods. Melphalan / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Sarcoma / drug therapy. Tumor Necrosis Factor-alpha / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Arm. Combined Modality Therapy. Female. Humans. Leg. Male. Middle Aged

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15915375.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  •  go-up   go-down


14. Abe S, Tokizaki T, Miki Y, Tateishi A, Ogawa K, Nakano H, Matsushita T: Hyperthermic isolated regional perfusion with CDDP for bone and soft-tissue sarcoma of the lower limb: pharmacokinetics, thermal dose, toxicity, and feasibility. Cancer Chemother Pharmacol; 2005 Jul;56(1):55-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperthermic isolated regional perfusion with CDDP for bone and soft-tissue sarcoma of the lower limb: pharmacokinetics, thermal dose, toxicity, and feasibility.
  • The objectives of this study were to investigate the pharmacokinetics of cisplatin (CDDP) and the thermal dose, toxicity, and feasibility of hyperthermic isolated regional perfusion (HIRP) with CDDP for bone and soft-tissue sarcomas of the lower limb.
  • The dose of CDDP administered was 62.9+/-11.8 mg/limb (20 mg/m(2) +20 approximately 30 mg).
  • The highest temperature within tumor was 42.3+/-1.4 degrees C on average.
  • The mean necrotic ratio in the resected specimen was 84.5%, and the effect was grade IV (no viable tumor cells) in 13 patients, grade III(>90% necrosis) in 12, grade II (50 to <90%) in 9, and grade I (<50%) in 4.
  • We obtained favorable levels of platinum concentration of the perfusate using a lower CDDP dosage compared with previous studies of HIRP.
  • Considering our results of the pharmacokinetics of CDDP and clinical efficacy, we propose a lower dosage of CDDP for HIRP in the treatment of osteosarcoma.
  • Multimodality treatment of HIRP with preoperative chemotherapy and surgery is a relatively safe and reliable therapeutic option for patients with limb sarcomas, and our method offers excellent local control.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Agents / pharmacokinetics. Bone Neoplasms / drug therapy. Chemotherapy, Cancer, Regional Perfusion. Cisplatin / administration & dosage. Cisplatin / pharmacokinetics. Sarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Combined Modality Therapy. Dose-Response Relationship, Drug. Female. Humans. Leg / pathology. Male. Middle Aged. Temperature. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15791455.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


15. Schoeler D, Lindner T, Schulenburg S, Von der, Pink D, Reichardt P: Coincidence of retinoblastoma and leiomyosarcoma in father and daughter - a rare case report. J Clin Oncol; 2004 Jul 15;22(14_suppl):9059

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Father: The 54-years old male was diagnosed with unilateral retinoblastoma of his right eye in 1950 and underwent enucleation in the age of 1, he was not treated by chemotherapy or radiation in the childhood.
  • In 2000 a leiomyosarcoma of his right lower leg with pulmonary metastases was diagnosed.
  • He was treated by polychemotherapy, radiotherapy and surgery of lung and soft tissue metastases.
  • At the moment the patient is treated by a fourth line chemotherapy with ET-743.
  • She underwent a chemotherapy with epirubicin/ifosfamide followed by surgery.
  • Since that time the situation remains stable.
  • CONCLUSIONS: The propensity for survivors of heritable retinoblastoma to develop second nonocular malignancies is well known, they can occur within the field of irradiation (case of the daughter) or fail previous radiation or chemotherapy (case of the father).
  • In the presented family the grandchild is also affected by retinoblastoma, fortunately it is under local control by laser therapy.
  • With this familial history systematic screening for tumor symptoms should be performed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014098.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Jun HJ, Lee J, Lim DH, Park JO, Ahn G, Seo SW, Sung KS, Lim DH, Yoo KH, Choi YL: Expression of MET in alveolar soft part sarcoma. Med Oncol; 2010 Jun;27(2):459-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of MET in alveolar soft part sarcoma.
  • Alveolar soft part sarcoma (ASPS) is a rare soft tissue sarcoma which is characterized by the presence of a specific chromosomal translocation encoding the chimeric transcription factor (ASPL-TFE3) that activates expression of MET.
  • We reviewed the clinical features and treatment outcome of 12 ASPS patients.
  • Lower extremity was the most commonly affected primary site (2 thigh, 3 lower leg, and 1 foot).
  • Of four patients who received primary cytotoxic chemotherapy, no patient demonstrated treatment response.
  • The high expression of MET in ASPL-TFE3 (+) ASPS may further support the potential role of targeted agents against MET in this rare, chemoresistant tumor.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Proto-Oncogene Proteins c-met / biosynthesis. Receptors, Growth Factor / biosynthesis. Sarcoma, Alveolar Soft Part / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Female. Foot / pathology. Humans. Leg / pathology. Male. Middle Aged. Retrospective Studies. Thigh / pathology. Young Adult

  • Genetic Alliance. consumer health - Alveolar Soft Part Sarcoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Top Pathol. 1995;89:1-16 [7882705.001]
  • [Cites] Cell Res. 2005 Jan;15(1):49-51 [15686627.001]
  • [Cites] Ann Oncol. 2000 Nov;11(11):1445-9 [11142485.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):919-29 [17283122.001]
  • [Cites] Adv Anat Pathol. 1999 May;6(3):125-39 [10342010.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):4130-5 [11358836.001]
  • [Cites] Cancer. 2001 Feb 1;91(3):585-91 [11169942.001]
  • [Cites] Cancer. 1985 Feb 15;55(4):912-7 [3967185.001]
  • [Cites] Nature. 2003 Oct 16;425(6959):727-33 [14562105.001]
  • [Cites] Oncogene. 2001 Jan 4;20(1):48-57 [11244503.001]
  • [Cites] Jpn J Clin Oncol. 1999 May;29(5):245-7 [10379335.001]
  • [Cites] J Pediatr Hematol Oncol. 2008 Jan;30(1):46-52 [18176180.001]
  • [Cites] Science. 2007 May 18;316(5827):1039-43 [17463250.001]
  • [Cites] Cancer. 1989 Jan 1;63(1):1-13 [2642727.001]
  • [Cites] Cancer. 1987 Jul 1;60(1):66-73 [2438029.001]
  • [Cites] Oncology. 2003;65(1):7-13 [12837977.001]
  • [Cites] Ann Surg. 1987 Apr;205(4):349-59 [3566372.001]
  • (PMID = 19472090.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Growth Factor; EC 2.7.10.1 / MET protein, human; EC 2.7.10.1 / Proto-Oncogene Proteins c-met
  •  go-up   go-down


17. Lasithiotakis K, Economou G, Gogas H, Ioannou C, Perisynakis K, Filis D, Kastana O, Bafaloukos D, Decatris M, Catodritis N, Frangia K, Papadakis G, Magarakis M, Tsoutsos D, Chrysos E, Chalkiadakis G, Zoras O: Hyperthermic isolated limb perfusion for recurrent melanomas and soft tissue sarcomas: feasibility and reproducibility in a multi-institutional Hellenic collaborative study. Oncol Rep; 2010 Apr;23(4):1077-83
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperthermic isolated limb perfusion for recurrent melanomas and soft tissue sarcomas: feasibility and reproducibility in a multi-institutional Hellenic collaborative study.
  • Hyperthermic isolated limb perfusion with TNF-alpha and melphalan (TM-HILP) is a complicated surgical procedure.
  • Herein, we present the experience of the Hellenic collaborating centers with TM-HILP for inoperable in-transit melanoma and soft tissue sarcoma (STS) of the extremities to examine safety and feasibility of collaborating as a multi-institutional group for future research studies.
  • All patients underwent a 90-min isolated limb perfusion with melphalan (10 mg/l limb volume) and TNF-alpha (1-2 mg) under mild hyperthermia (39-40 degrees C).
  • No major intra-operative complications occurred and all patients completed the procedure successfully.
  • One patient developed postoperative ischemic necrosis of the limb necessitating amputation.
  • All STS patients attained complete response after excision of residual tumor.
  • The median disease specific and limb-relapse-free survival was 15 and 12 months, respectively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Chemotherapy, Cancer, Regional Perfusion / methods. Hyperthermia, Induced / methods. Melanoma / drug therapy. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Feasibility Studies. Female. Greece. Humans. Leg. Male. Melphalan / administration & dosage. Melphalan / adverse effects. Middle Aged. Reproducibility of Results. Retrospective Studies. Tumor Necrosis Factor-alpha / administration & dosage. Tumor Necrosis Factor-alpha / adverse effects

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20204294.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  •  go-up   go-down


18. Nachmany I, Subhi A, Meller I, Gutman M, Lahat G, Merimsky O, Klausner JM: Efficacy of high vs low dose TNF-isolated limb perfusion for locally advanced soft tissue sarcoma. Eur J Surg Oncol; 2009 Feb;35(2):209-14
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of high vs low dose TNF-isolated limb perfusion for locally advanced soft tissue sarcoma.
  • AIMS: The administration of a high dose of rTNF-alpha (3-4 mg) and Melphalan via isolated limb perfusion (ILP) for patients with locally advanced limb STS was shown to be effective.
  • Reports that a low dose of TNF (1mg) is as effective, led to the adoption of the low dose regimen as the treatment of choice.
  • The purpose of this study was to compare two groups of patients with locally advanced limb STS, that was treated with high and low dose TNF-ILP, in terms of limb preservation.
  • ILP/TNF was performed on candidates to either amputation or significantly mutilating surgery without this treatment.
  • In both groups, all patients, with the exception of three in each group, underwent resection of the residual tumor or tumor bed or limb 8-12 weeks after the procedure.
  • RESULTS: In the HD group, marked tumor softening occurred within 48 h, and in tumors protruding through the skin, hemorrhagic necrosis was evident within 24h.
  • Five patients achieved a CR and 10 had a PR; in five of these patients >90% necrosis of the tumor occurred.
  • The rate of limb sparing was 69.5%.
  • Of the remaining 15 patients, limb preservation was achieved in 53.3%.
  • CONCLUSION: Despite the retrospective comparison and possible selection bias, it is possible to raise the concern that at least some patients may benefit from a higher TNF dose perfusion in ILP for advanced limb STS.
  • [MeSH-major] Chemotherapy, Cancer, Regional Perfusion. Sarcoma / drug therapy. Tumor Necrosis Factor-alpha / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Arm. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Leg. Male. Middle Aged. Retrospective Studies. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18295442.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


19. Sobel E, Giorgini R, Oropeza R, Bapat K, Richardson H: Limb salvage in recurrent synovial sarcoma of the right ankle and lower leg. J Am Podiatr Med Assoc; 2002 Feb;92(2):90-6
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limb salvage in recurrent synovial sarcoma of the right ankle and lower leg.
  • Synovial sarcoma of the extremities represents 7% of all soft-tissue sarcomas.
  • This article presents the case of a patient who was treated for a synovial sarcoma of the lateral aspect of the distal lower leg extending to the ankle and involving the fibular bone.
  • The patient underwent a wide excision of the tumor, including the fibular bone, followed by radiation and chemotherapy, rather than undergo an amputation of the right leg.
  • Consideration is also given to the traumatic etiology of the tumor.
  • [MeSH-major] Bone Neoplasms / therapy. Limb Salvage / methods. Neoplasm Recurrence, Local / therapy. Sarcoma, Synovial / surgery
  • [MeSH-minor] Adult. Ankle. Biopsy, Needle. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Leg. Osteotomy / methods. Radiotherapy, Adjuvant. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11847260.001).
  • [ISSN] 8750-7315
  • [Journal-full-title] Journal of the American Podiatric Medical Association
  • [ISO-abbreviation] J Am Podiatr Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Ramirez RN, Otsuka NY, Apel DM, Bowen RE: Desmoid tumor in the pediatric population: a report of two cases. J Pediatr Orthop B; 2009 May;18(3):141-4
Genetic Alliance. consumer health - Desmoid Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoid tumor in the pediatric population: a report of two cases.
  • They tend to extensively infiltrate surrounding tissues, complicating the treatment.
  • We present the report of two cases of desmoid tumor in the pediatric population.
  • The first patient had tumor that necessitated removal of most of the anterior compartment of his leg.
  • The tumor in the second case was intimately involved with neurovascular structures and, therefore adjuvant treatment including chemotherapy and repeat surgery was necessary.
  • [MeSH-major] Fibromatosis, Aggressive / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Child. Combined Modality Therapy. Humans. Infant. Leg / surgery. Male. Neoplasm Recurrence, Local. Tendon Transfer. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19322113.001).
  • [ISSN] 1473-5865
  • [Journal-full-title] Journal of pediatric orthopedics. Part B
  • [ISO-abbreviation] J Pediatr Orthop B
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Siebenrock KA, Hertel R, Ganz R: Unexpected resection of soft-tissue sarcoma. More mutilating surgery, higher local recurrence rates, and obscure prognosis as consequences of improper surgery. Arch Orthop Trauma Surg; 2000;120(1-2):65-9
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unexpected resection of soft-tissue sarcoma. More mutilating surgery, higher local recurrence rates, and obscure prognosis as consequences of improper surgery.
  • Sixteen referred patients were reviewed after excision of an unexpected soft-tissue sarcoma of the extremities.
  • Postoperative magnetic resonance imaging (MRI) scans showed a poor negative predictive value for residual tumor.
  • Repeated resection, including three amputations, revealed residual tumor in 10 patients (63%).
  • Four patients received adjuvant local radiation, with additional chemotherapy in 2 of them.
  • At an average follow-up of 4.5 years (range 15-149 months), 4 patients (25%) had developed distant metastases with a local recurrence in 3 (19%).
  • There was one tumor-related death (6%).
  • Evaluation by adequate imaging techniques, biopsy, and definitive resection and reconstruction should be performed by an oncologically trained orthopaedic surgeon.
  • [MeSH-major] Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Amputation. Chemotherapy, Adjuvant. Female. Forearm. Humans. Leg. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Radiotherapy, Adjuvant. Reoperation. Shoulder

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10653107.001).
  • [ISSN] 0936-8051
  • [Journal-full-title] Archives of orthopaedic and trauma surgery
  • [ISO-abbreviation] Arch Orthop Trauma Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] GERMANY
  •  go-up   go-down


22. Zhao J, Han B, Shen T, Zhao Y, Wang T, Liu Y, Fang K, Zhong D, Ling Q: Primary cutaneous diffuse large B-cell lymphoma (leg type) after renal allograft: case report and review of the literature. Int J Hematol; 2009 Jan;89(1):113-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous diffuse large B-cell lymphoma (leg type) after renal allograft: case report and review of the literature.
  • We report a case of a 58-year-old man who presented with a rapidly growing proliferative lesion on the left lower limb, clinically resembling a soft tissue sarcoma 3 years after renal allograft.
  • There was no evidence of systemic involvement on bone marrow needle aspiration and computed tomography (CT) scans of the chest and abdomen.
  • The lesion turned out to be primary cutaneous diffuse large B-cell lymphoma, leg type (PCLBCL LT), as defined in the recent World Health Organization-European Organization for Research and Treatment of Cancer (WHO-EORTC) classification of cutaneous lymphomas by skin biopsy.
  • Immunosuppression reduction, chemotherapy with CHOP regimen and local radiotherapy induced complete remission of the tumor.
  • [MeSH-minor] Humans. Leg / pathology. Male. Middle Aged. Neoplasm Invasiveness. Remission Induction / methods. Skin Neoplasms / etiology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3602-10 [11504742.001]
  • [Cites] Pediatr Transplant. 2005 Oct;9(5):622-6 [16176420.001]
  • [Cites] J Cardiovasc Pharmacol Ther. 2006 Mar;11(1):77-83 [16703222.001]
  • [Cites] Arch Dermatol. 2004 Sep;140(9):1140-6 [15381556.001]
  • [Cites] Blood. 2005 May 15;105(10):3768-85 [15692063.001]
  • [Cites] Clin Transplant. 2005 Oct;19(5):668-73 [16146560.001]
  • [Cites] Br J Dermatol. 2005 Nov;153(5):874-80 [16225594.001]
  • [Cites] Transplant Proc. 2006 Mar;38(2):641-5 [16549195.001]
  • [Cites] Transplant Proc. 2007 May;39(4):1071-3 [17524894.001]
  • [Cites] Clin Transplant. 2005 Jun;19(3):327-34 [15877793.001]
  • [Cites] Am J Transplant. 2006 Nov;6(11):2735-42 [17049061.001]
  • [Cites] Am J Clin Pathol. 2002 Apr;117(4):574-80 [11939732.001]
  • [Cites] Arch Dermatol. 2007 Sep;143(9):1144-50 [17875875.001]
  • [Cites] Transplantation. 2005 Sep 15;80(5):595-9 [16177631.001]
  • [Cites] Transplant Proc. 2006 Oct;38(8):2448-50 [17097963.001]
  • [Cites] Blood. 2002 Feb 1;99(3):800-5 [11806979.001]
  • [Cites] J Cutan Pathol. 2005 Nov;32(10):647-74 [16293178.001]
  • [Cites] Transplantation. 2006 Mar 27;81(6):888-95 [16570013.001]
  • [Cites] Arch Dermatol. 2005 Sep;141(9):1139-45 [16172311.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2006 Oct;18(10):1065-70 [16957512.001]
  • [Cites] Transplantation. 2005 Jul 27;80(2):193-7 [16041263.001]
  • (PMID = 19109733.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 21
  •  go-up   go-down


23. Grünhagen DJ, de Wilt JH, Verhoef C, van Geel AN, Eggermont AM: TNF-based isolated limb perfusion in unresectable extremity desmoid tumours. Eur J Surg Oncol; 2005 Oct;31(8):912-6
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TNF-based isolated limb perfusion in unresectable extremity desmoid tumours.
  • BACKGROUND: Desmoid tumours are soft tissue sarcomas with local aggressive behaviour and a high rate of local recurrence after treatment.
  • Although they do not tend to metastasise systemically, the local aggressiveness can lead to situations in which limb-preserving surgery cannot be performed without severe disability.
  • As isolated limb perfusion (ILP) with TNF and melphalan has proven to be extremely effective in the treatment of soft tissue sarcoma, we studied its potential in locally advanced extremity desmoid tumours.
  • Local surgical therapy with preservation of limb function was impossible in all patients due to large or multifocal tumours, multiple recurrences or extensive previous treatment.
  • Perfusions were performed with 4-3mg TNF and 10-13 mg/l limb volume melphalan form leg and arm perfusions, respectively.
  • Local control was obtained after 10/12 ILPs and in the other two patients through repeat ILP and systemic chemotherapy, thus leading to an overall local control rate of 100%.
  • CONCLUSION: ILP is a very effective treatment option in the multimodality treatment of limb desmoid tumours.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Chemotherapy, Cancer, Regional Perfusion. Dermoid Cyst / drug therapy. Lower Extremity / pathology. Melphalan / administration & dosage. Soft Tissue Neoplasms / drug therapy. Tumor Necrosis Factor-alpha / administration & dosage. Upper Extremity / pathology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease Progression. Female. Humans. Limb Salvage. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Prospective Studies. Remission Induction. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16098709.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  •  go-up   go-down


24. Eggermont AM, de Wilt JH, ten Hagen TL: Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol; 2003 Jul;4(7):429-37
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current uses of isolated limb perfusion in the clinic and a model system for new strategies.
  • Isolated limb perfusion with melphalan is the treatment of choice for multiple (small) melanoma-in-transit metastases.
  • The use of tumour necrosis factor alpha (TNFalpha) in isolated limb perfusion is successful for treatment of locally advanced limb soft-tissue sarcomas and other large tumours; this approach can avoid the need for amputation.
  • TNFalpha was approved in Europe after a multicentre trial in patients with locally advanced soft-tissue sarcomas, deemed unresectable by an independent review committee; the response rate to isolated limb perfusion with TNFalpha plus melphalan was 76% and the limb was saved in 71% of patients.
  • Moreover, the trial showed the efficacy of isolated limb perfusion of TNFalpha and melphalan against various other limb-threatening tumours such as skin cancers and drug-resistant bony sarcomas.
  • Laboratory models of isolated limb perfusion have helped to elucidate mechanisms of action and to develop new treatment modalities.
  • They have identified TNFalpha-mediated vasculotoxic effects on the tumour vasculature and have shown that addition of TNFalpha to the perfusate results in an increase of three to six times in uptake of melphalan or doxorubicin by tumours.
  • New vasoactive drugs and new mechanisms of action are being discovered.
  • Moreover, isolated limb perfusion is an effective modality for gene therapy mediated by an adenoviral vector.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Chemotherapy, Cancer, Regional Perfusion / methods. Melanoma / pathology. Melphalan / therapeutic use. Sarcoma. Soft Tissue Neoplasms. Tumor Necrosis Factor-alpha / therapeutic use
  • [MeSH-minor] Aged. Aged, 80 and over. Animals. Female. Humans. Leg. Rats. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12850194.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  • [Number-of-references] 75
  •  go-up   go-down


25. Noorda EM, Vrouenraets BC, Nieweg OE, Van Coevorden F, Kroon BB: Isolated limb perfusion: what is the evidence for its use? Ann Surg Oncol; 2004 Sep;11(9):837-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated limb perfusion: what is the evidence for its use?
  • BACKGROUND: This study was conducted to assess the best available evidence for the use of isolated limb perfusion.
  • METHODS: Following the principles of Evidence-Based Medicine, we reviewed the best available evidence for isolated limb perfusion (ILP) for melanoma and soft tissue sarcoma (STS) of the limb.
  • Therapeutic M-ILP, with or without tumor-necrosis factor alpha and interferon gamma (T(I)M-ILP), seems indicated in unresectable melanoma (level 3 to 4 evidence).
  • In unresectable STS of the limbs, limb salvage can be obtained in 57% to 86% of patients with neoadjuvant T(I)M-ILP (level 3 evidence).
  • A comparison of level 3 to 4 studies on ILP and other neoadjuvant treatment modalities for unresectable STS shows that ILP results in the highest limb salvage rate with the lowest complication rate.
  • Level 1 and 2b evidence does show an effect of prophylactic ILP on micrometastatic disease in locoregional (recurrent) melanoma of the limb.
  • ILP seems the most effective limb sparing, neoadjuvant treatment modality when compared with other neoadjuvant treatment options for unresectable STS of the limb (level 3 to 4 evidence), although randomized studies are lacking.
  • [MeSH-major] Chemotherapy, Cancer, Regional Perfusion. Melanoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Sarcoma / drug therapy. Skin Neoplasms / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Arm. Evidence-Based Medicine. Humans. Leg. Neoadjuvant Therapy. Neoplasm Metastasis / prevention & control. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15313738.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  •  go-up   go-down


26. Bula P, Bula-Sternberg J, Wollina U, Haroske G, Bonnaire F: [Marjolin's ulcer: malignant transformation of a crural ulcer due to posttraumatic chronic osteomyelitis]. Unfallchirurg; 2010 Feb;113(2):149-54
MedlinePlus Health Information. consumer health - Leg Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report on the case of an 81-year-old female patient who developed a squamous cell carcinoma in a long-lasting therapy-resistant crural ulcer of the lower leg due to posttraumatic chronic osteomyelitis.
  • Eventually the lower leg had to be amputated because of massive destruction of soft tissue and the tibia bone.
  • Based on the desolate wound conditions plastic reconstruction by a pivoted muscle flap and surgical covering with mesh graft plastic was also necessary.The amputation stump had completely healed 6 months after surgery and the patient is fitted with an artificial limb ensuring independent mobility even outside the home.
  • Up to the present there is no evidence of any tumor recurrence or progression.
  • [MeSH-major] Amputation. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Cell Transformation, Neoplastic / pathology. Leg Injuries / pathology. Leg Injuries / surgery. Leg Ulcer / pathology. Leg Ulcer / surgery. Osteomyelitis / pathology. Osteomyelitis / surgery. Pseudomonas Infections / pathology. Pseudomonas Infections / surgery. Pseudomonas aeruginosa. Skin Ulcer / pathology. Tibia / surgery. Wounds, Penetrating / pathology. Wounds, Penetrating / surgery
  • [MeSH-minor] Aged, 80 and over. Artificial Limbs. Chronic Disease. Disease Progression. Drug Resistance, Bacterial. Female. Humans. Magnetic Resonance Imaging. Neoplasm Staging. Skin / pathology

  • Genetic Alliance. consumer health - Osteomyelitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Orthop Relat Res. 1999 May;(362):181-9 [10335297.001]
  • [Cites] J South Orthop Assoc. 1999 Fall;8(3):181-7 [12132863.001]
  • [Cites] Rev Rhum Engl Ed. 1996 Jan;63(1):62-4 [9064114.001]
  • [Cites] J Dtsch Dermatol Ges. 2008 Jul;6(7):569-72 [18248496.001]
  • [Cites] Br J Dermatol. 1995 Oct;133(4):571-4 [7577586.001]
  • [Cites] Acta Orthop Belg. 1993;59(4):327-32 [8116362.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2007 Aug;21(7):935-41 [17659003.001]
  • [Cites] Adv Dermatol. 1987;2:19-46 [3079255.001]
  • [Cites] Arch Dermatol. 1992 Nov;128(11):1486-9 [1444502.001]
  • [Cites] Med J Aust. 1996 Jun 17;164(12):718-20 [8668077.001]
  • [Cites] South Med J. 2005 Oct;98(10):1053 [16295826.001]
  • [Cites] Dermatol Online J. 2007 May 01;13(2):27 [17498446.001]
  • [Cites] Indian J Cancer. 1996 Sep;33(3):139-44 [9055488.001]
  • [Cites] J Burn Care Rehabil. 1990 Sep-Oct;11(5):460-9 [2246317.001]
  • [Cites] Int J Dermatol. 1991 Jan;30(1):58-61 [1993569.001]
  • [Cites] Int Orthop. 2001;25(6):389-91 [11820449.001]
  • [Cites] J Foot Surg. 1981 Fall;20(3):136-41 [7276451.001]
  • [Cites] J Bone Joint Surg Am. 1990 Jan;72(1):12-8 [2295659.001]
  • [Cites] J Clin Pathol. 1963 Nov;16:573-80 [14076377.001]
  • [Cites] Ann Dermatol Venereol. 1993;120(10):675-8 [8161096.001]
  • [Cites] Orthop Rev. 1991 Jul;20(7):625-8 [1945509.001]
  • [Cites] Ann Surg. 1981 May;193(5):598-605 [7235765.001]
  • [Cites] J Dermatol Surg Oncol. 1994 Feb;20(2):141-3 [8113507.001]
  • [Cites] J Mal Vasc. 2001 Apr;26(2):85-91 [11319413.001]
  • [Cites] Clin Orthop Relat Res. 1985 Sep;(198):264-7 [4028559.001]
  • [Cites] Dermatol Surg. 1996 Dec;22(12):1015-8 [9078313.001]
  • [Cites] J Natl Cancer Inst. 1992 Feb 19;84(4):235-41 [1734084.001]
  • [Cites] Rev Chir Orthop Reparatrice Appar Mot. 2007 Feb;93(1):63-71 [17389826.001]
  • [Cites] Skeletal Radiol. 2001 Jun;30(6):331-7 [11465774.001]
  • [Cites] Arch Phys Med Rehabil. 1986 Nov;67(11):831-3 [3778183.001]
  • (PMID = 19859679.001).
  • [ISSN] 1433-044X
  • [Journal-full-title] Der Unfallchirurg
  • [ISO-abbreviation] Unfallchirurg
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


27. Hohenberger P, Tunn PU: Isolated limb perfusion with rhTNF-alpha and melphalan for locally recurrent childhood synovial sarcoma of the limb. J Pediatr Hematol Oncol; 2003 Nov;25(11):905-9
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated limb perfusion with rhTNF-alpha and melphalan for locally recurrent childhood synovial sarcoma of the limb.
  • The use of isolated, hyperthermic limb perfusion (ILP) for locally recurrent synovial sarcoma in two children is reported.
  • ILP was performed using high-dose recombinant tumor necrosis factor alpha (rhTNF alpha) combined with melphalan via an extracorporeal circulation.
  • Six weeks later, the former tumor bed and irradiation field was excised together with myocutaneous flap reconstruction for soft tissue coverage.
  • The resection specimen revealed extensive necrosis of the tumor in both cases.
  • Six months after completion of treatment, near-perfect limb function was determined by general clinical assessment and validated scoring systems.
  • ILP, an accepted technique in treating adult extremity sarcoma, might also be of value in children as a means of limb-saving therapy.
  • [MeSH-major] Chemotherapy, Cancer, Regional Perfusion / methods. Melphalan / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Sarcoma, Synovial / drug therapy. Tumor Necrosis Factor-alpha / administration & dosage
  • [MeSH-minor] Adolescent. Child. Female. Humans. Leg. Male. Recombinant Proteins / administration & dosage

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14608203.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  •  go-up   go-down






Advertisement